FIELD: pharmaceuticals.
SUBSTANCE: invention relates to a method of obtaining form 1 of the ketoprofen-lysine co-crystal characterized by an x-ray pattern with characteristic peaks at 16.3; 17.5; 17.6; 17.7; 19.6; 19.7° 2-theta ± 0.20°, where the ratio of the quantities of ketoprofen and lysine molecules is 1:1, including: a) preparing a saturated solution of ketoprofen; b) mixing a saturated solution of ketoprofen with lysine; where the ratio of equivalents of ketoprofen in saturated solution and lysine is from 3:1 to 1:1; where the solvent used for the saturated solution of ketoprofen is selected from alcohols, where the said alcohols are selected from the group consisting of the following: 1-butanol, 1-propanol, 2-butanol, 2-propanol, 1-pentanol and benzyl alcohol; esters, where these esters are selected from the group consisting of the following: ethyl acetate, methyl acetate, propyl acetate; amide, where the said amide is N,N-dimethylacetamide; a ketone, where the said ketone is 4-methyl-2-pentanone; aromatic solvents, where these aromatic solvents are selected from the group consisting of the following: toluene, benzonitrile, p-xylene; a halogenated solvent, wherein the said halogenated solvent is dichloromethane; and their mixtures; and where the ratio of the mass of lysine (mg) to the volume (ml) of a saturated solution of ketoprofen is from 5 mg/ml to 60 mg/ml.
EFFECT: method has been developed for obtaining form 1 of the ketoprofen-lysine co-crystal, which is highly crystalline and can be used in medicine as an effective agent for the treatment of pain and inflammatory diseases.
2 cl, 17 dwg, 13 tbl
Title | Year | Author | Number |
---|---|---|---|
NEW CRYSTAL FORM OF VASCULAR PERMEABILITY BLOCKER COMPOUND | 2020 |
|
RU2809162C2 |
CRYSTALLINE PYRIMIDINYL-3,8-DIAZABICYCLO[3.2.1]OCTANYLMETHANONE AND ITS APPLICATIONS | 2020 |
|
RU2803145C2 |
NOVEL POLYMORPHS AND SALTS | 2011 |
|
RU2573384C2 |
KETAMINE PAMOATE AND USE THEREOF | 2020 |
|
RU2825336C2 |
CRYSTALLINE FORMS OF 1-[(3R,4S)-4-CYANOTETRAHYDROPYRAN-3-YL]-3-[(2-FLUORO-6-METHOXY-4-PYRIDYL)AMINO]PYRAZOLE-4-CARBOXAMIDE | 2019 |
|
RU2828229C2 |
STABLE POLYMORPHIC FORM OF 6-FLUORO-9-METHYL-9H-BETA-CARBOLINE AND ITS APPLICATIONS | 2020 |
|
RU2806322C2 |
SALTS AND POLYMORPHS OF 8-FLUORO-2-{4-[(METHYLAMINO)METHYL]PHENYL}-1,3,4,5-TETRAHYDRO-6H-AZEPINO[5,4,3-cd]INDOL-6-ONE | 2011 |
|
RU2570198C2 |
9E-15-(2-PYRROLIDIN-1-YL-ETHOXY)-7,12,25-TRIOXA-19,21,24-TRIAZATETRACYCLO[18.3.1.1(2,5). 1(14,18)]HEXACOSA-1(24),2,4,9,14,16,18(26),20,22-NONAENE CITRATE SALT | 2010 |
|
RU2543721C2 |
VARIOUS FORMS OF 6-CHLORO-2-ETHYL-N-(4-(4-(4-(TRIFLUOROMETHOXY)PHENYL)PIPERIDIN-1-YL)BENZYL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE | 2019 |
|
RU2826176C2 |
CRYSTALLINE FORMS OF 6-[2-(METHYLCARBAMOYL)PHENYLSULFANYL]-3-E-[2-(PYRIDIN-2-YL)ETHENYL]INDAZOLE, SUITABLE FOR TREATMENT OF ABNORMAL GROWTH OF CELLS IN MAMMALS | 2008 |
|
RU2518898C2 |
Authors
Dates
2023-09-05—Published
2019-12-20—Filed